Certara, Inc.
A maker of biosimulation software that lets drug developers test medicines in virtual patients before real trials, Certara's tools include Simcyp, Phoenix, and Chemaxon, and are used by researchers and regulators around the world. It was formed in 2008 from the merger of Tripos and Pharsight, two pioneers in molecular modeling and clinical trial simulation. The coined name "Certara" echoes the word certainty — a nod to its aim of making drug development more predictable.
Bought 24.1K
Granted 15.8K
Granted 47.7K
Granted 15.8K
Granted 47.7K · Sold 51.2K
Granted 74.0K
Granted 59.8K
Granted 15.8K
Granted 15.8K
Granted 15.8K
Granted 15.8K
Granted 33.7K
Granted 15.8K
Granted 16.9K
Granted 10.8K
Granted 5.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Feehery William FCHIEF EXECUTIVE OFFICER, Director · 1 transaction | +4% | 2.36M | — | 24.1K | — |
| Cashman James E IIIDirector, Chairman · 1 transaction | +3.4% | 484.2K | 15.8K | — | — |
| Aspbury RobertPRESIDENT, PREDICTIVE TECH · 8 transactions | +8.1% | 321.7K | 47.7K | — | — |
| Walsh Matthew MDirector · 1 transaction | +8% | 213.3K | 15.8K | — | — |
| Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF · 9 transactions | -25.3% | 85.0K | 47.7K | — | 51.2K |
| Gallagher John EChief Financial Officer · 8 transactions | +20% | 62.1K | 74.0K | — | — |
| Resnick Jon MatthewChief Executive Officer, Director · 2 transactions | — | 59.8K | 59.8K | — | — |
| Collins CynthiaDirector · 1 transaction | +43.7% | 51.8K | 15.8K | — | — |
| Killefer NancyDirector · 1 transaction | +43.7% | 51.8K | 15.8K | — | — |
| Broshy EranDirector, Chairman · 1 transaction | +45.1% | 50.7K | 15.8K | — | — |
| Crane Rosemary ADirector · 1 transaction | +52.7% | 45.7K | 15.8K | — | — |
| Corcoran DanielSVP and General Counsel · 6 transactions | +403% | 39.9K | 33.7K | — | — |
| Reynders John V WChief Financial Officer, Director · 1 transaction | +147.1% | 26.5K | 15.8K | — | — |
| Anhalt RonaChief Human Resources Officer · 4 transactions | +267.3% | 19.0K | 16.9K | — | — |
| McKemey AdrianPresident, Drug Dev. Solutions · 2 transactions | — | 8.2K | 10.8K | — | — |
| Bedi ArjunDirector · 1 transaction | — | 5.5K | 5.5K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -27.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.